Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from VRTX

How IBD Stock Of The Day Vertex Is Stacking Up Billions In Potential Sales

Vertex is Wednesday's IBD Stock Of The Day. As the biotech eyes several blockbuster opportunities, VRTX stock is finding renewed support.

Investors Business Daily

Dow Jones Futures Rise On Bank Of Japan Surprise; Tesla, Moderna Lead Early Movers

Futures rose and yields fell as the Bank of Japan stayed dovish. The market rally paused while Tesla stock jumped. United Airlines, Moderna rose overnight. Microsoft job cuts loom.

Investors Business Daily

The No. 1 Biotech Stock to Buy for 2023

Biotech stock Vertex Pharmaceuticals (VRTX) outperformed its industry peers, gaining more than 30% over the past year. The company reported solid performance in the CF business and across the company in the last quarter. Moreover, VRTX is committed to delivering a diversified pipeline of transformative medicines and therapies. Hence, this…

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

3 Biotech Stocks to Help Boost Your Portfolio in January

Increased government initiatives and the rising adoption of biotechnology in healthcare and agriculture are likely to enhance the growth of the biotech industry. Hence, fundamentally sound biotech stocks Vertex Pharmaceuticals (VRTX), Biogen (BIIB), and Jazz Pharmaceuticals (JAZZ) might be ideal additions to your portfolio as they look well-positioned to capitalize…

StockNews.com

IBD Stock Of The Day Vertex Eyes A Brighter 2023 On Moderna, Crispr Plans

Vertex is the IBD Stock Of The Day. The FDA signed off on its newest study in cystic fibrosis, but VRTX stock is trading sideways.

Investors Business Daily

3 Biotech Stocks to Buy Before December and 1 to Sell

The biotech industry is increasingly gaining prominence due to the growing prevalence of chronic disease and advancements in drug discovery and development. Given the industry’s solid growth prospects, it could be wise to buy quality biotech stocks, Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), and United Therapeutics (UTHR). However, we think…

StockNews.com

2 Stocks to Buy That Will Grow Your Money Over Time

Cooling inflation is raising hopes of a slower pace of rate hikes ahead. Moreover, experts now see chances of the economy avoiding a recession. Hence, investors could consider buying quality stocks, Comcast (CMCSA) and Vertex Pharmaceuticals (VRTX), to capitalize on their solid fundamentals. Read more.

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

The 5 Best Stocks to Invest in for the Long Term

Despite current market uncertainties, the U.S. economy's long-term growth prospects are pretty viable. Experts believe inflation will fall dramatically in the coming year, and robust growth will follow. Therefore, investors could buy quality stocks Microsoft (MSFT), Vertex Pharmaceuticals (VRTX), Centene (CNC), Agilent Technologies (A), and Myers Industries (MYE), which seem…

StockNews.com

Market Rally Holds Key Levels, But This Has Been Difficult; Tesla Woes Continue

Dow Jones futures: The market rally found support but new buys struggled. Here are seven investing rules to follow. Tesla stock hit fresh bear-market lows.

Investors Business Daily

3 Stocks to Buy With Rising Recession and Rate Risk

The stock market continues to be a challenging environment with rising rates a potent headwind. So far, the economy has been stable enough so that earnings growth has not contracted, but this is unlikely to persist the longer the Fed stays hawkish. This article discusses characteristics of stocks that are…

StockNews.com

Dow Jones Futures: Apple Holds, Amazon Joins Megacap Meltdown; What To Do Now

Apple dipped after the iPhone giant topped views. Amazon crashed on guidance, joining the megacap earnings meltdown.

Investors Business Daily

Vertex Shrugs Off Recent Malaise With A Third-Quarter Beat-And-Raise

Vertex beat third-quarter expectations and raised its sales outlook, helping VRTX stock surge on Friday, shrugging off Thursday's pain.

Investors Business Daily

Vertex Pharmaceuticals Unusual Options Activity For October 27

A whale with a lot of money to spend has taken a noticeably bearish stance on Vertex Pharmaceuticals. Looking at options history for Vertex Pharmaceuticals (NASDAQ:VRTX) we detected 13 strange trades.

Benzinga

Let These 3 Stocks Lead You Through the Bear Market

Gloomy earning guidance halted the S&P 500’s three-day winning streak. Moreover, a recession seems apparent as the U.S. economy battles sky-high inflation, aggressive rate hikes, and geopolitical headwinds. With the bear market not over yet, we think fundamentally strong stocks Walmart (WMT), Cisco Systems (CSCO), and Vertex Pharmaceuticals (VRTX) might…

StockNews.com

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

S&P 500 Biotech Giant Vertex Leads 5 Stocks Showing Strength

S&P 500 giant Vertex and Cheniere Energy, the largest U.S. liquefied natural gas producer, are setting up bullishly in the bear market.

StockNews.com

2 No-Brainer Biotech Stocks to Buy Right Now and 1 to Sell

The biotech industry is set to benefit from continued investments in breakthrough developments and federal support. Against this backdrop, fundamentally strong biotech stocks Gilead Sciences (GILD) and Vertex Pharmaceuticals (VRTX) could be solid buys. However, Relmada Therapeutics (RLMD) might be best avoided considering its weak fundamentals. Read on….

Investors Business Daily

Dow Jones Futures Rise On U.K. U-Turn Ahead Of CPI Inflation Report

Stocks were quiet Wednesday, as investors avoided rallying into the CPI inflation report. EV plays Albemarle and Aehr Test Systems dived.

Investors Business Daily

Dow Jones Futures Rise, Bond Yields In Flux With Inflation Reports Due

Futures pared gains as the 10-year Treasury yield in flux with big inflation reports due. The S&P 500 is at bear market lows.

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

2 Top Biotech Stocks to Buy for the Long Haul and 1 to Sell

Government initiatives to expand domestic biotech production and research and rising private investments in advancing technologies are expected to boost the industry’s prospects. While we believe biotech stocks Vertex Pharmaceuticals (VRTX) and Biogen (BIIB) could be ideal investments for the long run, fundamentally weak Timber Pharmaceuticals (TMBR) might be best…

Investors Business Daily

IBD Stock Of The Day Vertex Pharma: Why Its 'Sandbox' Approach Is Unusual In Biotech

Vertex Pharmaceuticals is the IBD Stock Of The Day as VRTX stock climbs higher on expectations for its next act in gene editing.

StockNews.com

3 Stocks to Ride the Bear Market Rally

Stocks could be embarking on another bear market rally despite a plethora of challenges. One factor is we are entering a seasonally bullish period of the year. Another is the bullish technical setup following the undercut and recovery of the mid-June lows. 3 stocks that investors should consider buying to…

Investors Business Daily

Dow Jones Futures Fall: Market Rally At Pivotal Point; Tesla, Enphase Skid

The stock market rally showed resilience, as the Dow Jones slashed early losses, but is at a pivotal point. Tesla fell while Enphase plunged.

Investors Business Daily

Vertex Among 25 Market Leaders On The IBD Breakout Stocks Index

As the market shows signs of a rebound, Vertex, Enphase and Shockwave Medical are among 25 stocks to watch.

Investors Business Daily

Vertex Among 9 Stocks To Watch In Struggling Market

As the market indexes work through a downturn, Vertex is among nine stocks to watch showing relative strength.

Investors Business Daily

Vertex Stock Flashes Buy Signal; Gene-Editing Play Leads 5 Resilient Stocks In Bear Market

Vertex Pharmaceuicals flashed a buy signal last week on positive gene-editing news. It's one of several resilient stocks to watch in the bear market.

1 … 3 4 5 6

People

Mangeet Kaur BounsMangeet

Jaimini DesaiJaimini Desai

59 stories

David Risinger

34 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.